Data Presented at ACC Demonstrates Benefits of Keystone Heart’s TriGuard™ (Israel) Cerebral Protection Device During TAVR

Late breaking trials at the ACC include the data from the first randomized, multi-center DEFLECT III clinical trial, testing the TriGuard Cerebral Detection Device...

Read more

Israël Science Info